Psychemedics Corporation

Psychemedics Corporation is a United States laboratory-services company focused on detecting drugs of abuse through analysis of hair samples. Its corporate headquarters are in Acton, Massachusetts, while its laboratory operations are based in Culver City, California. The company serves institutional, workplace, educational, and other testing programs rather than operating primarily as a consumer healthcare brand. The business grew out of research led by Werner Baumgartner, a scientist who developed methods for identifying drug residues deposited in hair. Baumgartner's work attracted public attention after he examined hair associated with the nineteenth-century poet John Keats and reported evidence consistent with increasing opium exposure before Keats's death. The episode helped publicize the potential of hair as a historical record of drug exposure and was referenced in a 1985 Time magazine cover story concerning drugs in the workplace. Psychemedics was formed commercially in 1987 after research indicated that drug compounds and metabolites could be measured in the hair shaft. The company's approach differs from urine- or saliva-based testing. Drugs consumed by an individual enter the bloodstream and may become embedded in the cortex of growing hair. Because hair grows gradually and retains incorporated compounds, a sample cut close to the scalp can provide a longer detection window than a specimen collected from a body fluid. Psychemedics describes a standard head-hair sample of approximately one and one-half inches as representing roughly three months of exposure, although the precise window depends on hair growth, sample characteristics, drug type, and other testing conditions. The company commercialized hair testing for employers and organizations in sectors including banking, manufacturing, retail, mining, hotels, and casinos. Its testing menu has included cocaine, marijuana, opiates such as heroin and oxycodone, methamphetamine, MDMA, MDEA, and PCP. When head hair is unavailable, body hair may be used, although interpretation can differ from that of scalp hair. The company has also provided testing programs for schools and other institutions. Psychemedics historically used a proprietary radioimmunoassay approach and later adopted enzyme immunoassay screening, together with mass-spectrometry confirmation methods such as GC/MS/MS or LC/MS/MS. These procedures are intended to screen for target substances and then confirm detected drug molecules or metabolites. The company promotes hair testing as comparatively difficult to defeat through specimen substitution, adulteration, or a short period of abstinence. In 2013, Psychemedics introduced hair-based ethyl glucuronide testing intended to identify chronic excessive alcohol consumption. This offering attracted scientific and regulatory caveats. Hair alcohol-marker testing has recognized limitations and is not generally considered sufficient by itself to establish abstinence or moderate consumption. The U.S. Substance Abuse and Mental Health Services Administration has cautioned that such testing should not be the sole basis for legal or disciplinary action because environmental exposure to alcohol-containing products can complicate interpretation. The supplied reference material also states that the U.S. Food and Drug Administration had not cleared Psychemedics' EtG alcohol test at the time described. Psychemedics has maintained an international distribution relationship in Brazil through Psychemedics Brazil. Samples collected at Brazilian clinics have been shipped to the company's Culver City laboratory for analysis. The brand's market position rests on specialized laboratory expertise, a long detection window, and institutional drug-testing programs, while the reliability, interpretation, and appropriate use of hair testing remain important considerations for clients and regulators.

Psychemedics Corporation's history is rooted in the development of hair analysis for drug detection. Before the company was formed, Werner Baumgartner researched how substances consumed by a person could become incorporated into growing hair. His work helped establish the scientific and commercial premise that hair may preserve evidence of drug exposure over a period of months, in contrast with body-fluid specimens whose detection windows are generally shorter. Baumgartner became publicly associated with the field after examining hair attributed to the poet John Keats. The analysis was reported as showing increasing opium exposure before Keats's death, most likely connected with medicinal pain treatment. The unusual historical application helped attract wider attention, and Baumgartner's work was discussed in connection with a 1985 Time magazine cover story about drugs in the workplace. In 1978, Baumgartner developed a radioimmunological method for detecting drug use from hair specimens. Following years of research into the measurement of drug deposits in hair, Psychemedics was established in 1987 and began offering the technology commercially. The company targeted organizations seeking drug-testing programs, including banks, manufacturers, retailers, mining businesses, hotels, and casinos. The company's testing model is based on analysis of the hair shaft. As drugs and their metabolites circulate in the bloodstream, some may become embedded in the cortex of newly growing hair. A scalp-hair sample taken near the root can therefore provide a retrospective record extending over several months. Psychemedics has described a typical one-and-one-half-inch sample as covering approximately three months, based on an average growth rate of about one-half inch per month. Body hair can be collected when scalp hair is unavailable, but differences in growth patterns affect interpretation. Psychemedics initially used its own radioimmunoassay technology and later moved to enzyme immunoassay screening, with confirmation by tandem mass spectrometry techniques including GC/MS/MS and LC/MS/MS. Its drug panels have covered cocaine, cannabis, opiates, methamphetamine, MDMA, MDEA, and PCP. The company has emphasized that hair specimens are less easily substituted or adulterated than some fluid specimens and are less affected by a person's stopping drug use for only a few days before collection. The business expanded beyond conventional workplace testing into school and institutional programs. It also developed an international distribution presence in Brazil through Psychemedics Brazil, an independent distributor that collected specimens at clinics and arranged shipment to the company's Culver City, California, laboratory for analysis. In 2013, Psychemedics added hair-based ethyl glucuronide testing. The product was intended to identify chronic excessive alcohol use, but hair alcohol testing has significant interpretive constraints. Professional and government guidance has indicated that such testing should not be used alone to prove abstinence or moderate consumption, and that environmental exposure to alcohol-containing products can produce complications. The supplied reference material states that the FDA had not cleared Psychemedics' EtG alcohol test at the time under discussion. The company also faced reputational scrutiny over its school-testing business. In 2014, three private Cleveland-area schools selected Psychemedics. Coverage focused on the undisclosed family relationship between one participating school's principal and Psychemedics chief executive Raymond Kubacki. Earlier reporting also raised questions about the company hiring senior personnel from client organizations, including a school principal described as having become a Psychemedics vice president and spokesperson. These episodes placed emphasis on procurement transparency and potential conflicts of interest in institutional testing arrangements.

• 2014

  School-testing contract prompts conflict-of-interest scrutiny

  [1]Psychemedics Corporationen.wikipedia.org

  A Cleveland-area school-testing arrangement drew media attention because a participating principal was related to Psychemedics' chief executive.

• 2013

  Ethyl glucuronide hair testing introduced

  [1]Psychemedics Corporationen.wikipedia.org

  The company began offering hair-based EtG alcohol testing, accompanied by limitations concerning scientific interpretation and regulatory status.

• 1987

  Psychemedics is formed and begins commercial services

  [1]Psychemedics Corporationen.wikipedia.org

  Psychemedics was established to commercialize hair-based drug testing for institutional and workplace markets.

• 1985

  Hair drug analysis reaches wider public attention

  [1]Psychemedics Corporationen.wikipedia.org

  Baumgartner's research, including analysis associated with John Keats, was discussed in the context of a Time magazine cover story about drugs in the workplace.

• 1978

  Baumgartner develops a hair drug-testing method

  [1]Psychemedics Corporationen.wikipedia.org

  Werner Baumgartner developed a radioimmunological method for identifying drug use from hair specimens.

• 1858

  Early scientific evidence of substances in hair

  [1]Psychemedics Corporationen.wikipedia.org

  A report by Hoppe-Seyler described arsenic detected in the hair of an eleven-year-old buried body, contributing to the broader scientific history of using hair as a record of chemical exposure.

A specialized clinical laboratory brand positioned around hair-based drug detection, extended detection windows, and testing programs for employers, schools, and other institutions.

• Clinical laboratory service · 1987

  Hair-based drug testing

  Psychemedics' core offering analyzes scalp or body hair for evidence of drugs and their metabolites. The company's standard scalp-hair approach uses a sample cut close to the scalp, with an approximately three-month retrospective window often associated with a one-and-one-half-inch sample. Testing has covered cocaine, marijuana, opiates, methamphetamine, MDMA, MDEA, and PCP. Screening is followed by confirmatory mass-spectrometry analysis when appropriate.

• Retail hair-testing product

  PDT90

  PDT90 is identified in the reference material as a Psychemedics retail hair-testing product. The supplied sources do not provide enough detail to describe its current formulation, distribution, or precise testing panel.

• Alcohol-use testing · 2013

  Hair-based ethyl glucuronide alcohol test

  Introduced in 2013, this test uses hair analysis for ethyl glucuronide, an alcohol-related marker, with the stated aim of identifying chronic excessive alcohol consumption. Professional guidance has warned that the result should not be treated as proof of abstinence or moderate consumption and should not be interpreted in isolation.

• 2014

  Cleveland-area school testing conflict-of-interest controversy

  After three private Cleveland-area schools announced hair-testing arrangements with Psychemedics, reporting highlighted that St. Edward's High School principal James Kubacki was the brother of Psychemedics chief executive Raymond Kubacki. The relationship was reported as not having been disclosed to parents during institutional meetings about the testing policy.

  Source

Read more

• 2013

  Add hair-based ethyl glucuronide testingProduct launch

  Background

  Psychemedics sought to extend its hair-analysis platform beyond illicit-drug detection into alcohol-use assessment.

  Action taken

  The company began offering a hair-based ethyl glucuronide test intended to identify chronic excessive alcohol consumption.

  Aftermath

  The offering remained subject to scientific and regulatory caveats. Guidance cited in the reference material stated that hair EtG results should not be used alone to establish abstinence or support legal or disciplinary action, and the FDA had not cleared Psychemedics' test at the time described.

  Source

• 1987

  Commercialize hair-based drug testingStrategy

  Background

  Research led by Werner Baumgartner indicated that drug deposits in hair could be measured over a longer period than many body-fluid tests.

  Action taken

  Psychemedics was formed and began marketing hair-testing laboratory services to commercial and institutional customers.

  Aftermath

  The company developed a specialized position in workplace, school, and other organizational drug-testing programs.

  Source

1. 1Psychemedics Corporationen.wikipedia.org